NASDAQ: LYEL

Company Deals

Lyell Immunopharma Secures Global Rights to LYL273 CAR‑T Therapy – Major Step Toward mCRC Treatment

Fineline Cube Nov 11, 2025

Lyell Immunopharma, Inc. (NASDAQ: LYEL) announced the execution of a definitive licensing agreement with Innovative...

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod